Trial Profile
Safety and immunogenicity of meningococcal vaccine group B OMV (MenBvac) in healthy subjects.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2015
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B OMV (Primary)
- Indications Meningococcal group B infections
- Focus Pharmacodynamics
- Sponsors Chiron Vaccines
- 05 Nov 2010 New trial record.